Logo image of OBSV

OBSEVA SA (OBSV) Stock Fundamental Analysis

NASDAQ:OBSV - Nasdaq - CH0346177709 - Common Stock - Currency: USD

0.1018  -0.02 (-15.52%)

After market: 0.0826 -0.02 (-18.86%)

Fundamental Rating

1

OBSV gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 562 industry peers in the Biotechnology industry. OBSV may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, OBSV is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OBSV had negative earnings in the past year.
OBSV had a negative operating cash flow in the past year.
OBSV Yearly Net Income VS EBIT VS OCF VS FCFOBSV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -20M -40M -60M -80M -100M

1.2 Ratios

The profitability ratios for OBSV are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OBSV Yearly ROA, ROE, ROICOBSV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OBSV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OBSV Yearly Profit, Operating, Gross MarginsOBSV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 -100K -200K -300K -400K -500K

More info and screens

0

2. Health

2.1 Basic Checks

OBSV does not have a ROIC to compare to the WACC, probably because it is not profitable.
OBSV has more shares outstanding than it did 1 year ago.
OBSV has a better debt/assets ratio than last year.
OBSV Yearly Shares OutstandingOBSV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M
OBSV Yearly Total Debt VS Total AssetsOBSV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M

2.2 Solvency

OBSV has an Altman-Z score of -45.57. This is a bad value and indicates that OBSV is not financially healthy and even has some risk of bankruptcy.
OBSV has a worse Altman-Z score (-45.57) than 91.76% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -45.57
ROIC/WACCN/A
WACC8.72%
OBSV Yearly LT Debt VS Equity VS FCFOBSV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M

2.3 Liquidity

OBSV has a Current Ratio of 0.61. This is a bad value and indicates that OBSV is not financially healthy enough and could expect problems in meeting its short term obligations.
OBSV has a worse Current ratio (0.61) than 91.76% of its industry peers.
OBSV has a Quick Ratio of 0.61. This is a bad value and indicates that OBSV is not financially healthy enough and could expect problems in meeting its short term obligations.
OBSV's Quick ratio of 0.61 is on the low side compared to the rest of the industry. OBSV is outperformed by 91.28% of its industry peers.
Industry RankSector Rank
Current Ratio 0.61
Quick Ratio 0.61
OBSV Yearly Current Assets VS Current LiabilitesOBSV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 50M 100M

More info and screens

5

3. Growth

3.1 Past

OBSV shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.94%.
Looking at the last year, OBSV shows a very negative growth in Revenue. The Revenue has decreased by -57.43% in the last year.
The Revenue has been growing by 298.56% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)6.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110%
Revenue 1Y (TTM)-57.43%
Revenue growth 3Y901.88%
Revenue growth 5Y298.56%
Sales Q2Q%-81.53%

3.2 Future

Based on estimates for the next years, OBSV will show a very strong growth in Earnings Per Share. The EPS will grow by 26.26% on average per year.
The Revenue is expected to grow by 11.07% on average over the next years. This is quite good.
EPS Next Y12.85%
EPS Next 2Y32.71%
EPS Next 3Y26.26%
EPS Next 5YN/A
Revenue Next Year-33.03%
Revenue Next 2Y-41.42%
Revenue Next 3Y14.26%
Revenue Next 5Y11.07%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
OBSV Yearly Revenue VS EstimatesOBSV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2026 2027 10M 20M 30M 40M
OBSV Yearly EPS VS EstimatesOBSV Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -0.5 -1 -1.5 -2 -2.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OBSV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OBSV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OBSV Price Earnings VS Forward Price EarningsOBSV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OBSV Per share dataOBSV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

OBSV's earnings are expected to grow with 26.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.71%
EPS Next 3Y26.26%

More info and screens

0

5. Dividend

5.1 Amount

OBSV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OBSEVA SA

NASDAQ:OBSV (3/22/2023, 8:20:53 PM)

After market: 0.0826 -0.02 (-18.86%)

0.1018

-0.02 (-15.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-09 2023-03-09
Earnings (Next)08-15 2023-08-15
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners11.95%
Ins Owner Change0%
Market Cap8.60M
Analysts45.71
Price Target12.24 (11923.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.4%
Min EPS beat(2)-121.65%
Max EPS beat(2)98.85%
EPS beat(4)2
Avg EPS beat(4)-2.12%
Min EPS beat(4)-121.65%
Max EPS beat(4)98.85%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)51188.3%
Min Revenue beat(2)45.28%
Max Revenue beat(2)102331%
Revenue beat(4)3
Avg Revenue beat(4)25589.6%
Min Revenue beat(4)-40.77%
Max Revenue beat(4)102331%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)84.62%
PT rev (3m)157.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.79
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS0.1
BVpS-0.04
TBVpS-0.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.29%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.61
Quick Ratio 0.61
Altman-Z -45.57
F-Score3
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)228.57%
Cap/Depr(5y)1654.55%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110%
EPS Next Y12.85%
EPS Next 2Y32.71%
EPS Next 3Y26.26%
EPS Next 5YN/A
Revenue 1Y (TTM)-57.43%
Revenue growth 3Y901.88%
Revenue growth 5Y298.56%
Sales Q2Q%-81.53%
Revenue Next Year-33.03%
Revenue Next 2Y-41.42%
Revenue Next 3Y14.26%
Revenue Next 5Y11.07%
EBIT growth 1Y23.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.03%
OCF growth 3YN/A
OCF growth 5YN/A